Children with incurable brain tumours could benefit from potentially life-extending treatment if genetic testing was used to personalise therapy as it is in many adults, major new research reports.
May 14, 2018
0
17
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.
Sep 15, 2017
0
2
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), ...
Feb 28, 2016
0
46
Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same ...
Aug 13, 2015
0
22
Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer.
Nov 14, 2014
0
0
Custom-made versions of a widely prescribed, low-cost drug used to prevent a leading cause of blindness in the elderly vary widely in their dosages, Weill Cornell Medical College scientists found in analyses of the eye injections. ...
Sep 19, 2014
0
0
The Food and Drug Administration has approved Genentech's Avastin for a new use against late-stage cervical cancer, the sixth indication for the blockbuster biotech drug.
Aug 15, 2014
0
0
An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.
Jul 19, 2013
0
0
There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected ...
Jun 18, 2013
0
0
A new cervical cancer drug offers the first good hope of extending life for women with advanced stages of the disease, according to a study published Sunday.
Jun 2, 2013
0
0
